open access publication

Article, 2022

Environmental Sustainability Analysis of L-Tryptophan as a Consumer Product and Intermediate to Pharmaceutical Active Ingredients

Frontiers in Sustainability, ISSN 2673-4524, Volume 3, Page 863914, 10.3389/frsus.2022.863914

Contributors

Overcash, Alan [1] [2] Griffing, Evan Michael [1] [2] Sukumara, Sumesh 0000-0002-7924-458X [3] Overcash, Michael R 0000-0002-6291-6159 (Corresponding author) [1] [2]

Affiliations

  1. [1] Environmental Clarity, Inc., Reston, VA, United States
  2. [NORA names: United States; America, North; OECD];
  3. [2] Environmental Genome Initiative, Sautee Nacoochee, GA, United States
  4. [NORA names: United States; America, North; OECD];
  5. [3] Technical University of Denmark
  6. [NORA names: DTU Technical University of Denmark; University; Denmark; Europe, EU; Nordic; OECD]

Abstract

L-tryptophan is a naturally occurring α-amino acid that is also purchased by consumers for medicinal and dietary purposes. L-tryptophan is also a starting point for synthesizing medical derivatives with antiplatelet aggregation and antibacterial activity. Beneficial direct use and subsequent synthetic product use were evaluated with respect to the environmental footprint of the cradle-to-L-tryptophan manufacturing process, using the next generation life cycle inventory technology of the Environmental Genome. The principal route is fermentation from sugar (dextrose). The environmental metrics quantified were natural resource energy combustion (NREc) and CO2eq for air (defined below). The environmental boundary includes 137 chemical intermediates (gate-to-gates, gtg), of which 33 are non-repeating, with the most consequential for the environmental metrics being dextrose and the L-tryptophan. The cradle-to-gate process energy is 147 MJ/kg L-tryptophan, while the more comprehensive natural resource energy combustion (NREc) is 222 MJ/kg L-tryptophan. The carbon footprint is 18.7 kg CO2equivalent/kg L-tryptophan, with 53% of this from the cradle-to-gate of the supply chains. It is important to note this is only a partial environmental assessment of L-tryptophan since the environmental benefits of use in consumption and when used to make preventative pharmaceuticals are not included.

Keywords

CO2eq, Environmental, L-tryptophan, a-amino acids, acid, active ingredients, activity, aggregation, air, antibacterial activity, antiplatelet, antiplatelet aggregation, benefits, boundaries, carbon, carbon footprint, chain, chemical, chemical intermediates, combustion, consumer products, consumers, consumption, cradle-to-gate, cradle-to-gate processing energy, derivatives, dextrose, dietary purposes, direct use, energy, energy combustion, environmental benefits, environmental boundaries, environmental footprint, environmental genomics, environmental metrics, environmental sustainability analysis, fermentation, footprint, genome, ingredients, intermediate, inventory technology, manufacturing process, metrics, non-repeating, pharmaceutical active ingredients, pharmaceuticals, prevent pharmaceuticals, principal route, process, process energy, product use, production, purposes, route, sugar, supply, supply chain, technology, use

Funders

  • Novo Nordisk Foundation
  • European Commission

Data Provider: Digital Science